A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00001300 |
Recruitment Status :
Completed
First Posted : December 10, 2002
Last Update Posted : March 4, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Randomized study. All patients must be randomized to treatment on Arms I and II within 3 months of definitive surgery on Regimen A.
Regimen A: Surgery followed, as indicated, by Radiotherapy. Amputation; or limb-sparing resection followed by involved-field irradiation using megavoltage equipment with or without electron boost.
Arm I: 2-Drug Combination Chemotherapy with Hematologic Toxicity Attenuation and Urothelial Protection. Doxorubicin, DOX, NSC-123127; Ifosfamide, IFF, NSC-109724; with Granulocyte Colony Stimulating Factor (Amgen), G-CSF,
NSC-614629; and Mesna, NSC-113891.
Arm II: Observation. No adjuvant chemotherapy.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sarcoma | Drug: doxorubicin Drug: ifosfamide Drug: mesna | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 150 participants |
Primary Purpose: | Treatment |
Official Title: | A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma |
Study Start Date : | June 1992 |
Study Completion Date : | March 2001 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically proven AR and ESFT which includes: Classical, atypical and extraosseous Ewing's sarcoma, primitive peripheral neuroectodermal tumors, peripheral neuroepithelioma, primitive sarcoma of bone, and ectomesenchymoma.
Confirmed presence of tumor-specific infusion protein by documented RT-PCR which corresponds to one of the tumor specific peptides available for vaccination.
Measurable tumor.
No prior or current CNS metastases.
PRIOR/CONCURRENT THERAPY:
Arm A patients:
May be enrolled on the protocol for the first phase in the absence of RT PCR documentation of a tumor-specific fusion protein which corresponds to one of the tumor-specific peptides available for vaccination. However, RT PCR documentation at the time of tumor recurrence must occur prior to administration of immunotherapy. At time of initial tumor diagnosis, prior to any cytoreductive therapy.
Arm B patients:
Tumor recurrence occurring during or after receiving at least first line cytoreductive therapy for ESFT and AR. No more than two post-recurrence salvage regimens unless peripheral CD4+T cell number is greater than 400 cells per millimeter cubed.
At least 6 weeks since any treatments and recovered from all acute toxic effects from time in which immunotherapy will be started for this study.
No concurrent estrogen therapy during immunotherapy section of study.
PATIENT CHARACTERISTICS:
Age: 2-25 (at time of initial diagnosis of alveolar rhabdomyosarcoma).
Weight: Greater than 15 kg (at time of apheresis).
Performance status: ECOG 0-2.
Life expectancy: At least 8 weeks.
Hematopoietic:
ANC greater than 100,000/mm3.
Hemoglobin greater than 9.0 g/dL.
Platelet count greater than 50,000/mm3.
Hepatic:
Bilirubin less than 2.0 mg/dL (unless related to involvement by tumor).
Transaminases less than 3 times normal (unless related to involvement by tumor).
Renal:
Creatinine less than 1.5 mg/dL or creatinine clearance greater than 60 mL/min.
Cardiovascular:
No major disorder of cardiovascular system.
Cardiac ejection fraction greater than 40%.
Pulmonary:
No major disorder of pulmonary system.
Other:
Not pregnant or nursing.
HIV negative.
Hepatitis B or C negative.
No patients requiring daily oral corticosteroid therapy.
If allergic to eggs, egg products, or thimerosal, or have a history of Guillain-Barre syndrome, ineligible to receive influenza vaccine.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001300
United States, Maryland | |
National Cancer Institute (NCI) | |
Bethesda, Maryland, United States, 20892 |
ClinicalTrials.gov Identifier: | NCT00001300 |
Other Study ID Numbers: |
920210 92-C-0210 |
First Posted: | December 10, 2002 Key Record Dates |
Last Update Posted: | March 4, 2008 |
Last Verified: | April 2000 |
Adjuvant Chemotherapy Ifosfamide Randomized Study Soft Tissue Sarcoma |
Sarcoma Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms Doxorubicin Ifosfamide Antibiotics, Antineoplastic |
Antineoplastic Agents Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Alkylating Alkylating Agents |